title: [Limited 5-fluorouracil-induced systemic scleroderma].
authors.forename: S
authors.initials: S
authors.lastname: Benomar
authors.forename: S
authors.initials: S
authors.lastname: Boutayeb
authors.forename: L
authors.initials: L
authors.lastname: Benzekri
authors.forename: K
authors.initials: K
authors.lastname: Senouci
authors.forename: H
authors.initials: H
authors.lastname: Errihani
authors.forename: B
authors.initials: B
authors.lastname: Hassam
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003082:Colectomy; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D009543:Nifedipine / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D002121:Calcium Channel Blockers; D009543:Nifedipine; D005472:Fluorouracil